Meta Information
ID:magnesium-taurate
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-21T22:30:00Z
Model
phase-a-upgrade-claude-sonnet-4.6
Interactions
Target id:
/class/chelating-antibiotics
Target name:
Chelating Antibiotics (Tetracyclines, Quinolones)
Severity:
major
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
4
Description:
Magnesium binds to tetracycline and fluoroquinolone antibiotics in the gut, forming an insoluble complex that prevents their absorption and severely reduces their effectiveness.
Actionable advice:
Magnesium should be taken at least 2 hours before or 4 hours after these antibiotics.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
magnesium, calcium, and zinc can interfere with the gastrointestinal absorption of tetracycline antibiotics
Label source:
PubMed: International journal of molecular sciences (2019)
Source url:
Exact phrase from label:
when administered orally, reduced absorption and bioavailability can occur due to chelation in the gastrointestinal tract (GIT) with multivalent metal cations acquired from diet, coadministered compounds (sucralfate, didanosine), or drug formulation.
Label source:
PubMed: Pharmaceutics (2021)
Source url:
Exact phrase from label:
Chelation interactions with multivalent cations can result in inactivation of the fluoroquinolone with ramifications in vitro and in vivo. Chelation interactions have been reported to occur in between 22 and 76% of patients prescribed fluoroquinolones.
Label source:
PubMed: Drug safety (1995)
Action type:
separate
Target id:
/intervention/bisphosphonates
Target name:
Bisphosphonates
Severity:
major
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
2
Description:
Magnesium forms a complex with bisphosphonate drugs (e.g., alendronate for osteoporosis), significantly reducing their absorption from the intestine.
Actionable advice:
Doses of magnesium and bisphosphonates should be separated by at least 2 hours.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Instruct patients to take supplemental calcium and vitamin D if their dietary intake is inadequate; and to take calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations at a different time of the day
Label source:
FDA label: Risedronate (Actonel)
Action type:
separate
Target id:
/condition/renal-impairment
Target name:
Renal Impairment
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The kidneys are responsible for excreting excess magnesium. Impaired kidney function can lead to a toxic accumulation of magnesium in the blood (hypermagnesemia).
Actionable advice:
Magnesium supplements should not be used unless specifically prescribed and monitored by a physician.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Here we detail her clinical course, including the unique challenges of treating eclampsia and PRES in the setting of magnesium toxicity.
Label source:
PubMed: Posterior Reversible Encephalopathy Syndrome and Eclampsia in the Setting of Magnesium Toxicity: A Case Report. (PMID 37948545)
Action type:
avoid
Target id:
/class/proton-pump-inhibitors
Target name:
Proton Pump Inhibitors
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Chronic use of PPIs can severely impair the intestinal absorption of magnesium, leading to clinically significant hypomagnesemia over months or years.
Actionable advice:
Long-term PPI use can lower magnesium. If you take both, check magnesium levels periodically and supplement under medical guidance if low.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
5.8 Hypomagnesemia Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy.
Label source:
Action type:
monitor
Target id:
/condition/myasthenia-gravis
Target name:
Myasthenia Gravis
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Magnesium can inhibit the release of acetylcholine at the neuromuscular junction, which can worsen muscle weakness in individuals with myasthenia gravis.
Actionable advice:
Magnesium supplementation should be strictly avoided.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Magnesium is known to act at the neuromuscular junction by inhibiting the presynaptic release of acetylcholine and desensitizing the postsynaptic membrane. Because of these effects, magnesium has been postulated to potentiate neuromuscular weakness.
Label source:
PubMed: Texas Heart Institute journal (2015)
Source url:
Exact phrase from label:
Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease. Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission.
Label source:
PubMed: Muscle & nerve (1990)
Action type:
avoid
Target id:
/condition/heart-block
Target name:
Heart Block (AV Block)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
High levels of magnesium can slow electrical conduction in the heart, potentially worsening atrioventricular (AV) block.
Actionable advice:
Magnesium supplements should not be used unless approved and monitored by a cardiologist.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
In conclusion, magnesium increases tachycardia cycle length and AH interval in patients with dual AVN physiology through a dominant effect on the slow AVN pathway.
Label source:
Action type:
avoid
Target id:
/class/thyroid-hormones
Target name:
Thyroid Hormones
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
4
Hours after target:
4
Description:
Magnesium can bind to thyroid hormones like levothyroxine in the gut, impairing their absorption and potentially leading to reduced efficacy.
Actionable advice:
Doses of magnesium and thyroid medication should be separated by at least 4 hours.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Drugs That May Decrease T4 Absorption (Hypothyroidism) Potential impact: Concurrent use may reduce the efficacy of SYNTHROID by binding and delaying or preventing absorption, potentially resulting in hypothyroidism.
Label source:
Action type:
separate
Target id:
/intervention/calcium-supplements
Target name:
Calcium Supplements
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
2
Description:
High doses of calcium and magnesium compete for the same absorption pathways in the intestine, reducing the absorption of both minerals.
Actionable advice:
High-dose calcium and magnesium supplements should be separated by at least 2 hours.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
OBJECTIVE: In view of the widespread use of magnesium (Mg) as a nutritional supplement, we investigated whether Mg would affect the absorption of calcium (Ca) as the intestinal absorption sites for Mg and Ca differ.
Label source:
PubMed: Journal of the American College of Nutrition (1994)
Source url:
Exact phrase from label:
Intestinal interactions between Mg and calcium or phosphate have been demonstrated in both humans and animals. The nature of these interactions cannot be readily explained by data currently available.
Label source:
PubMed: The Journal of nutrition (1991)
Source url:
Exact phrase from label:
In the uptake medium (extracellular), magnesium was a noncompetitive inhibitor of saturable calcium transport, consistent with a regulatory role in calcium uptake by binding to the transporter at a locus other than that for calcium.
Label source:
PubMed: The American journal of physiology (1989)
Action type:
separate
Target id:
/intervention/iron-supplements
Target name:
Iron Supplements
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
2
Description:
High doses of magnesium can slightly reduce the absorption of non-heme iron supplements when taken at the same time due to competition for transporters. However further stuides are needed since this was established based on a single published case report of overuse of magnesium laxative.
Actionable advice:
Magnesium and iron supplements should be separated by at least 2 hours.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
Although in vitro studies show that iron absorption can be inhibited by magnesium laxatives such as magnesium oxide, taking oral iron supplements with magnesium laxatives is not considered a clinical problem.
Label source:
Action type:
separate
Target id:
/class/antihypertensives
Target name:
Antihypertensive Medications
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Magnesium and taurine both promote vasodilation and can lower blood pressure, potentially enhancing the effects of antihypertensive medications and increasing the risk of hypotension.
Actionable advice:
Blood pressure should be monitored closely when combining, and dose adjustments of medication may be needed.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
By a variety of mechanisms, magnesium functions both intracellularly and extracellularly to minimize the cytoplasmic free calcium level, [Ca2+]i. This may be the chief reason why correction of magnesium deficiency, or induction of hypermagnesemia by parenteral infusion, exerts antihypertensive, anti-atherosclerotic, anti-arrhythmic and antithrombotic effects.
Label source:
PubMed: Medical hypotheses (1996)
Source url:
Exact phrase from label:
The combination of increased intake of magnesium and potassium coupled with reduced sodium intake is more effective in reducing BP than single mineral intake and is often as effective as one antihypertensive drug in treating hypertension.
Label source:
PubMed: Journal of clinical hypertension (Greenwich, Conn.) (2011)
Source url:
Exact phrase from label:
The results showed that taurine increased serum levels of nitric oxide and nitric oxide synthase, inhibited the elevation of blood pressure, interfered with the activity of the renin-angiotensin-aldosterone system and minimized the elevation in serum cytokine, endothelin, neuropeptide Y and thromboxane B2.
Label source:
PubMed: Advances in experimental medicine and biology (2009)
Action type:
adjust_with_prescriber
Target id:
/class/antidiabetic-medications
Target name:
Diabetes Medications
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Both magnesium and taurine can improve insulin sensitivity and lower blood glucose, which may potentiate the effects of diabetes medications and increase the risk of hypoglycemia.
Actionable advice:
Blood glucose levels are best monitored carefully when starting magnesium taurate.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Label source:
Action type:
monitor
Target id:
/class/potassium-sparing-diuretics
Target name:
Potassium-Sparing Diuretics
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
These diuretics (e.g., spironolactone, amiloride) can reduce the excretion of magnesium, increasing the risk of hypermagnesemia (high magnesium levels) when taken with supplements.
Actionable advice:
High-dose magnesium supplements are best avoided unless under medical supervision.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
K-sparing diuretics are usually administered concomitantly with more potent diuretics to counteract diuretic-induced K depletion. These agents act in the late distal tubule and collecting duct. Evidence has accumulated in recent years indicating that these drugs may also exert some Mg-sparing properties.
Label source:
PubMed: Magnesium (1986)
Source url:
Exact phrase from label:
Spironolactone promotes magnesium and potassium retention, increases uptake of myocardial norepinephrine, attenuates formation of myocardial fibrosis, and decreases mortality associated with both progressive ventricular dysfunction and malignant ventricular arrhythmias.
Label source:
PubMed: Current hypertension reports (2000)
Source url:
Exact phrase from label:
Serum magnesium concentrations increased significantly (p=0.02) with time >20 weeks compared to baseline. CONCLUSIONS: The combination of an ACEI and spironolactone results in no significant difference between baseline and follow-up serum sodium or potassium concentrations. Although serum magnesium concentrations may increase significantly with time >20 weeks compared to baseline concentrations, hypermagnesemia appears to be rare, mild, and unlikely to be of clinical importance.
Label source:
PubMed: Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology (2007)
Action type:
avoid
Target id:
/class/loop-diuretics
Target name:
Loop Diuretics
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Loop diuretics (e.g., furosemide) increase the urinary excretion of magnesium, which can lead to magnesium deficiency over time.
Actionable advice:
Regular monitoring of magnesium levels is recommended; supplementation may be necessary.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Reference ID: 5673142
11 DESCRIPTION
Lasix ONYU (furosemide injection) for subcutaneous use is a loop diuretic.
Label source:
Action type:
monitor
Target id:
/class/thiazide-diuretics
Target name:
Thiazide Diuretics
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Long-term use of thiazide diuretics (e.g., hydrochlorothiazide) can increase magnesium loss through the kidneys, potentially causing depletion.
Actionable advice:
Magnesium status should be monitored if these medications are used long-term.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Common causes include alcoholism, type 2 diabetes mellitus and the use of pharmacological drugs, such as proton-pump inhibitors, calcineurin inhibitors and thiazide diuretics.
Label source:
PubMed: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)
Source url:
Exact phrase from label:
Gitelman syndrome and thiazide diuretics which inhibit sodium chloride cotransporter in the distal convoluted tubule are associated with hypokalemia, metabolic alkalosis, renal magnesium wasting, hypomagnesemia, and hypocalciuria.
Label source:
PubMed: Iranian journal of kidney diseases (2010)
Source url:
Exact phrase from label:
Many therapeutic agents cause renal Mg wasting and subsequent deficiency. These include loop and thiazide diuretics, aminoglycosides, cisplatin, pentamidine, and foscarnet.
Label source:
PubMed: American journal of kidney diseases : the official journal of the National Kidney Foundation (1994)
Action type:
monitor
Target id:
/intervention/vitamin-d
Target name:
Vitamin D
Severity:
moderate
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Magnesium is a required cofactor for the activation and metabolism of Vitamin D in the liver and kidneys. Adequate magnesium levels are necessary for Vitamin D to function properly.
Actionable advice:
Adequate magnesium intake is a good idea when supplementing with Vitamin D to support its efficacy.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
All of the enzymes that metabolize vitamin D seem to require magnesium, which acts as a cofactor in the enzymatic reactions in the liver and kidneys.
Label source:
PubMed: Role of Magnesium in Vitamin D Activation and Function. (PMID 29480918)
Action type:
informational_none
Target id:
/circadian/sleep
Target name:
Going to Sleep
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
1
Hours after target:
null
Description:
Both magnesium and taurine promote relaxation and support GABAergic neurotransmission, which can improve sleep onset and quality.
Actionable advice:
It is generally best taken 30-60 minutes before bedtime to support sleep.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The psycholeptic sedative effects of darkness, like those of magnesium, rely on direct membraneous and oxidant actions, neural mediated effects (i.e. stimulation of inhibitory neuromodulators such as GABA and taurine), and on antagonism of neuroactive gases (CO and NO).
Label source:
PubMed: Magnesium research (2002)
Source url:
Exact phrase from label:
The natural N-methyl-D-aspartic acid (NMDA) antagonist and GABA agonist, Mg(2+), seems to play a key role in the regulation of sleep.
Label source:
PubMed: Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences (2012)
Source url:
Exact phrase from label:
BC showed antioxidant potential, a sedative effect, was not toxic, and all doses of BC had an anxiolytic-like effect and showed potential for the treatment of alcohol withdrawal-induced anxiety in aZF. In addition to the anxiolytic action, the main chemical constituents of BC were confirmed in the molecular docking, thus suggesting that BC is an anxiolytic that modulates the GABAergic system and has pharmacological potential for the treatment of alcohol withdrawal-induced anxiety.
Label source:
PubMed: Neurochemistry international (2024)
Action type:
separate
Target id:
/class/cns-depressants
Target name:
CNS Depressants
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The taurine component has GABAergic effects and magnesium can have a calming effect, potentially leading to additive drowsiness or sedation when combined with other CNS depressants like benzodiazepines or alcohol.
Actionable advice:
This is best used with caution, keeping in mind the potential for increased drowsiness.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The psycholeptic sedative effects of darkness, like those of magnesium, rely on direct membraneous and oxidant actions, neural mediated effects (i.e. stimulation of inhibitory neuromodulators such as GABA and taurine), and on antagonism of neuroactive gases (CO and NO).
Label source:
PubMed: Magnesium research (2002)
Source url:
Exact phrase from label:
BC showed antioxidant potential, a sedative effect, was not toxic, and all doses of BC had an anxiolytic-like effect and showed potential for the treatment of alcohol withdrawal-induced anxiety in aZF. In addition to the anxiolytic action, the main chemical constituents of BC were confirmed in the molecular docking, thus suggesting that BC is an anxiolytic that modulates the GABAergic system and has pharmacological potential for the treatment of alcohol withdrawal-induced anxiety.
Label source:
PubMed: Neurochemistry international (2024)
Source url:
Exact phrase from label:
Glutamic and aspartic acids both excited cell activity while gamma-aminobutyric acid (GABA), muscimol, taurine, beta-alanine and delta-aminolaevulinic acid all inhibited activity.
Label source:
PubMed: General pharmacology (1990)
Action type:
informational_none
Target id:
/intervention/zinc
Target name:
Zinc
Severity:
minor
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
2
Description:
Very high doses of zinc can impair magnesium absorption, and vice-versa, due to competition for intestinal transporters.
Actionable advice:
For optimal absorption, high-dose zinc and magnesium supplements are best separated by at least 2 hours.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Zn supplements of 142 mg/day decreased Mg absorption and the Mg balance significantly during all Ca intakes for the three groups combined.
Label source:
PubMed: Journal of the American College of Nutrition (1994)
Source url:
Exact phrase from label:
magnesium, calcium, and zinc can interfere with the gastrointestinal absorption of tetracycline antibiotics
Label source:
PubMed: International journal of molecular sciences (2019)
Source url:
Exact phrase from label:
The indiscriminate use of mineral supplements can adversely affect physiologic function and impair health.
Label source:
PubMed: The American journal of clinical nutrition (2000)
Action type:
separate
Target id:
/dietary/phytate-rich-foods
Target name:
Phytate-Rich Foods (Grains, Legumes, Nuts)
Severity:
minor
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
1
Hours after target:
1
Description:
Phytates found in whole grains, legumes, and nuts can bind to magnesium in the gut, forming an insoluble salt and reducing its absorption.
Actionable advice:
Magnesium is generally best taken at least 1 hour away from meals very high in phytates for best absorption.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
FA is known as a dietary inhibitor that chelates minerals and trace elements, limiting their bioavailability and reducing their absorption.
Label source:
PubMed: [The role of phytates in human nutrition]. (PMID 37801451)
Action type:
separate
Target id:
/dietary/oxalate-rich-foods
Target name:
Oxalate-Rich Foods (Spinach, Rhubarb, Beets)
Severity:
minor
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
1
Hours after target:
1
Description:
Oxalates, present in foods like spinach and rhubarb, can bind with magnesium to form insoluble magnesium oxalate, which is poorly absorbed.
Actionable advice:
Magnesium is generally best taken at least 1 hour away from meals very high in oxalates.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
apparent Mg absorption was significantly lower from the meal served with spinach (26.7 (sd 10.4) %) than the meal served with kale (36.5 (sd 11.8) %) (P=0.01). Although based on indirect evidence, the difference in Mg absorption observed in the present study is attributed to the difference in oxalic acid content between the two vegetables
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/15035687/
Action type:
separate
Target id:
/intervention/vitamin-b6
Target name:
Vitamin B6
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Vitamin B6 (in its P5P form) is a cofactor that facilitates the transport of magnesium into cells, potentially enhancing its intracellular effectiveness.
Actionable advice:
Consider taking with a B-complex or a small dose of Vitamin B6 (P5P).
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Mg deficiency impairs vitamin B6 status by depleting intracellular Mg and thus inhibits the activity of alkaline phosphatase, a metalloenzyme required for the uptake of pyridoxal phosphate by tissues.
Label source:
PubMed: Journal of the American College of Nutrition (1997)
Source url:
Exact phrase from label:
Both Mg chloride and Mg L-aspartate in combination with vitamin B6 caused statistically significant compensation of magnesium deficit.
Label source:
PubMed: Vestnik Rossiiskoi akademii meditsinskikh nauk (2010)
Source url:
Exact phrase from label:
Menstruating females also often present with low magnesium (Mg) and vitamin B6 levels. Vitamin B6 moderates intracellular nitric oxide (NO) production and extracellular Mg is required for NO release from the cell, so that a deficiency of these nutrients results in increased NO production in the cell and reduced release from the cell.
Label source:
PubMed: Medical hypotheses (2000)
Action type:
informational_none